Sinovac Biotech Ltd SVA Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$6.47 unchanged at close Nov 6
Last close · Previous close $6.47
- 52-week change
- unchangedPrice only
- Distributions
- $0.00Per share, last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$6.47unchangedFri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$6.47Nov 5
- Volume0.00Nov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume0.00Last 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $6.47 to $6.47; now $6.47
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
SVA beat the S&P 500 in 4 of 6 periods.
| Period | SVA and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | SVA: unchanged S&P 500: down 5.6% | SVA beat the S&P 500 by 5.6 percentage points Beat |
| 3M | SVA: unchanged S&P 500: down 4.1% | SVA beat the S&P 500 by 4.1 percentage points Beat |
| YTD | SVA: unchanged S&P 500: up 8.7% | SVA trailed the S&P 500 by 8.7 percentage points Trailed |
| 1Y | SVA: unchanged S&P 500: up 10.9% | SVA trailed the S&P 500 by 10.9 percentage points Trailed |
| Long term | ||
| 5Y | SVA: up 850.1% S&P 500: up 67.8% +56.9% vs +10.9% a year | SVA beat the S&P 500 by 782.3 percentage points Beat |
| 10Y | SVA: up 907.7% S&P 500: up 313.1% +26.0% vs +15.2% a year | SVA beat the S&P 500 by 594.6 percentage points Beat |
$10,000 invested in SVA 10 years ago (Nov 4, 2016) would be worth about $100,770 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
SVA beat the S&P 500 in 2 of 6 periods.
| Period | SVA and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | SVA: unchanged S&P 500: down 5.6% | SVA beat the S&P 500 by 5.6 percentage points Beat |
| 3M | SVA: unchanged S&P 500: down 4.3% | SVA beat the S&P 500 by 4.3 percentage points Beat |
| YTD | SVA: unchanged S&P 500: up 7.8% | SVA trailed the S&P 500 by 7.8 percentage points Trailed |
| 1Y | SVA: unchanged S&P 500: up 9.7% | SVA trailed the S&P 500 by 9.7 percentage points Trailed |
| Long term | ||
| 5Y | SVA: unchanged S&P 500: up 56.9% 0.0% vs +9.4% a year | SVA trailed the S&P 500 by 56.9 percentage points Trailed |
| 10Y | SVA: up 6.1% S&P 500: up 252.6% +0.6% vs +13.4% a year | SVA trailed the S&P 500 by 246.5 percentage points Trailed |
$10,000 invested in SVA 10 years ago (Nov 4, 2016) would be worth about $10,607 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$10.46
Closing high on . Now 38.1% below that record.
Split-adjusted daily closes since Nov 3, 2003.
Stock splits
SVA hasn’t split since its price history begins in 2003.
Dividends
Cash dividends per share by ex-dividend year, adjusted for splits.
Dividends per share
Data table
| Year | Per share |
|---|---|
| 2016 | $0.000 |
| 2017 | $0.000 |
| 2018 | $0.000 |
| 2019 | $0.000 |
| 2020 | $0.000 |
| 2021 | $0.000 |
| 2022 | $0.000 |
| 2023 | $0.000 |
| 2024 | $0.000 |
| 2025 | $55.00 |
| 2026 (to date) | $0.000 |
Dividend details
- $0.00Per share, last 12 months
Cash dividends per share with ex-dividend dates in the last 12 months.
- 0.00%; 5-yr low 850.08%, 5-yr high 850.08%Last 12 months
Dividends paid over the last 12 months as a share of the Nov 6 close. The bar shows where that yield sits in its range over the past five years; the median was 850.08%.
- $55.00Ex-dividend
The most recent payment per share. Shares bought on or after the ex-dividend date don’t receive it.
About Sinovac Biotech Ltd
SINOVAC Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus71 (EV71), hepatitis A and B, seasonal influenza, 23-Valent pneumococcal polysaccharide ("PPV"), H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella and mumps. SINOVAC's COVID-19 vaccine, CoronaVac®, has been granted emergency use approval or conditional marketing authorization by over 40 countries or regions worldwide. Healive®, the hepatitis A vaccine manufactured by the Company, has passed the assessment under WHO prequalification procedures in 2017. The EV71 vaccine, an innovative vaccine developed by SINOVAC against hand foot and mouth disease caused by EV71, was commercialized in China in 2016. In 2009, SINOVAC was the first company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program. The Company is developing several new products including a Sabin-strain inactivated polio vaccine and combined vaccines. SINOVAC primarily sells its vaccines in China, while also exploring growth opportunities in international markets. The Company is seeking market authorization of its products in over 30 countries outside of China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- China
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
SVA news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
SVA stock FAQ
What is SVA stock’s price today?
Sinovac Biotech (SVA) traded at $6.47 at the close on , unchanged from the previous close of $6.47. Over the past 52 weeks it has traded between $6.47 and $6.47.
If you invested $1,000 in SVA 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in SVA on would be worth about $10,077 at the close on , a total return of +907.7%. The same $1,000 would be worth $9,501 if invested five years ago, $1,000 if invested one year ago, and $18,856 if invested 20 years ago. Past performance doesn’t predict future returns.
What is Sinovac Biotech’s market cap?
Sinovac Biotech’s market capitalization is about $644.7 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $6.47 (how market cap works).
Does SVA pay a dividend?
Sinovac Biotech hasn’t paid a dividend in the last twelve months.
What is SVA’s 52-week high and low?
Over the past 52 weeks SVA has traded as low as $6.47 and as high as $6.47. At $6.47 at the close on , it is 0.0% below that high and 0.0% above the low.
What is SVA’s all-time high?
SVA’s highest closing price was $10.46 on , adjusted for stock splits. At $6.47 at the close on , it is 38.1% below that record.
Has SVA stock ever split?
No. SVA hasn’t split since its price history begins in 2003.
How has SVA stock performed?
Including dividends and measured to the close on , SVA has returned 0.0% so far this year and 0.0% over the past year, and +850.1% over five years (+56.9% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Sinovac Biotech in?
Sinovac Biotech is in the Healthcare sector and the Biotechnology industry, and is headquartered in China.
What exchange does SVA trade on?
Sinovac Biotech trades on the Nasdaq under the ticker symbol SVA. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.